Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan.

@article{Huang2012ImmunogenicityAS,
  title={Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan.},
  author={Li-Min Huang and T. -Y. Lin and Christine Juergens},
  journal={Vaccine},
  year={2012},
  volume={30 12},
  pages={2054-9}
}
UNLABELLED Immunogenicity and safety of 13-valent and 7-valent pneumococcal conjugate vaccines (PCV13; PCV7) were compared in Taiwanese children. In this double-blind, multicenter study, healthy children were randomly assigned to receive PCV13 (n=84) or PCV7 (n=84) at 2, 4, 6 and 15 months with routine pediatric vaccines. For the 7 PCV13/PCV7 common serotypes, serotype-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) were high 1 month postinfant series, with ≥95.0% in both… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 18 references

( PCV 13 ) elicits cross - functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6 C and 7 A

  • NH Kim, J Lee, SJ Lee, H Lee, KH Kim, SE Park
  • 2011

compared to a 7 - valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany

  • SH Yeh, A Gurtman, DC Hurley, SL Block, RH Schwartz, S Patterson
  • VACCINE
  • 2010

( diphtheria CRM ( 197 ) protein conjugate ; Prevenar ) in Korean infants : differences that are found in Asian children

  • LH Lee, CE Frasch, LA Falk, DL Klein, CD Deal
  • 2007

Similar Papers

Loading similar papers…